ECTRIMS 2016: Optimally Managing Patients with Multiple Sclerosis through Individualized Treatment Options
This CME program focuses on content presented during 2016 ECTRIMS Annual Meeting in London, United Kingdom on September 14 – 17, 2016. This activity educates healthcare providers involved in the management of patients with multiple sclerosis (MS) with the goal of presenting the most comprehensive analysis for clinical decision-making. This includes the role of the comprehensive healthcare team in the initiation of therapy, as well as effectively communicating therapeutic decisions to the patient. Faculty members assess patient-specific treatment plans to improve outcomes for patients with multiple sclerosis.
This activity has been designed to meet the educational needs of neurologists and other healthcare professionals who care for patients with MS.
Upon completion of this activity, participants will be able to:
- Review novel science presented at ECTRIMS 2016.
- Examine clinical trial data of disease modifying therapies presented at ECTRIMS 2016.
- Develop strategies for applying up-to-date data to the management of patients with multiple sclerosis.
Fred D. Lublin, MD
Clyde Markowitz, MD
|Claire Riley, MD|
Assistant Professor of Neurology
Director, Multiple Sclerosis Clinical Care & Research Center
Columbia University Medical Center
New York-Presbyterian Hospital
New York, NY
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Faculty||Relationship Identified With:|
Fred D. Lublin, MD
Consultant/Advisor: Acorda Therapeutics, Inc.; Actelion Pharmaceuticals US, Inc.; Akros Pharma Inc.; Bayer AG; BBB Therapeutics; Biogen; Celgene Corporation; EMD Serono, Inc.; Forward Pharma; Genentech, Inc.; Genzyme Corporation; F. Hoffmann-La Roche Ltd; Mallinckrodt; MedImmune; Novartis Pharmaceuticals Corporation; Osmotica Pharmaceutical Corp.; Receptos Services LLC; sanofi-aventis U.S. LLC; Teva Pharmaceutical Industries Ltd.; XenoPort, Inc.
Grant/Research Support: Biogen; Celgene Corporation; Genzyme Corporation; National Institutes of Health; Novartis Pharmaceuticals Corporation; Teva Pharmaceutical Industries Ltd.; Transparency Life Sciences
Stock Ownership: Cognition Pharmaceuticals, Inc.
Clyde E. Markowitz, MD
Consultant/Advisor: Bayer AG; Biogen; EMD Serono, Inc.; Genentech, Inc.; Genzyme Corporation; Novartis Pharmaceuticals Corporation; Opexa Therapeutics, Inc.; F. Hoffmann-La Roche Ltd; Teva Pharmaceutical Industries Ltd
|Claire Riley, MD||Consultant/Advisor: Biogen; EMD Serono, Inc.; Genzyme Corporation; Novartis Pharmaceuticals Corporation; Teva Pharmaceutical Industries Ltd.; Neuroscience|
Non-faculty: Sandy Breslow; Alison Kemp; Leah Johnson; Bernard M. Abrams, MD; Timothy Hayes, MD, PhD; Emma Gilmartin; Nicole Brestowski; and Megan Gentile hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
This CME activity has been supported by an independent educational grant from Genzyme Corporation.
Co-provided by the Elsevier Office of Continuing Medical Education and AcademicCME.
CME Credit (Physicians)
The Elsevier Office of Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credit™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at email@example.com
AANP Credit (Nurse Practitioners)
This activity is approved for 1.0 contact hour(s) of continuing education by the American Association of Nurse Practitioners. Activity ID 16112437. This activity was planned in accordance with the AANP CE Standards and Policies.
CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Elsevier Office of Continuing Medical Education, AcademicCME, and Genzyme Corporation do not recommend the use of any agent outside of the labeled indications.
Disclaimer Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 1.00 AANP
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 Non-physician